NYU Langone Health

Clinicians at Population Health Roundtables shared obesity care innovations, from pharmacist-led models to same-day liver screening

He sees progress in Richter combination therapies, explains how patient goals shape CLL treatment, and reflects on mentoring trainees.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Kittai, of Perlmutter Cancer Center, discusses choosing therapies to fit patients’ lives and how mentoring energizes him.

Novel combinations may improve survival in Richter transformation, a hard-to-treat condition, says Adam Kittai, MD, of Perlmutter Cancer Center.

Clinicians outline fragmented obesity and diabetes care models, insurance-driven prescribing, and early results from Medicare's GLP-1 bridge program.

Drugs that form the backbone of CLL therapy are also used across lymphoma subtypes, explains Adam S. Kittai, MD.

Fix cardiorenalmetabolic care gaps: define ownership, task-shift screening, boost uACR testing, and tackle obesity-driven equity barriers.

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today.

Adam Kittai, MD, reviews AMPLIFY data supporting acalabrutinib-venetoclax (AV) for CLL, citing strong safety and survival outcomes for select patients.

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short.

Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens.

Adam Kittai, MD, weighs the favorable safety profile of acalabrutinib plus venetoclax against lingering unknowns on long-term efficacy and high-risk patients.

Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.

Discussions at this February IVBM evening covered advances in biomarker testing in lung cancer to the real-life challenges of maintaining diversity in clinical trials.

Communicating to patients that they need to come to their annual checkup is important for eye doctors to convey to help treat their patients, says Ariana Levin, MD.

Experts discuss the signs and symptoms, treatment methods, and the future of glaucoma as Glaucoma Awareness Month concludes.

Experts raise concerns that CDC childhood immunization changes could reduce vaccine uptake and weaken trust in public health guidance.

Using artificial intelligence (AI) to specialize treatment for patients with different kinds of cancer can be a boon to clinicians looking to personalize their care.

Experts discuss the evolution of cancer care, emphasizing value-based approaches, precision oncology, and the importance of multidisciplinary collaboration for improved patient outcomes.

New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best therapeutic options for patients with cancer.

Children and adults should watch where they are walking and avoid any thrown objects when participating in Halloween festivities to protect their eyes.

Using masks that tie up in the back and being aware of environmental factors can help protect eyes during Halloween trick-or-treating.

A session held during the CHEST 2025 Annual Meeting focused on the North American guidelines for treating bronchiectasis.

Aspects of the average Halloween costume could pose risks to the corneal health of the eye if not applied correctly.

The symptoms of dry eye are multifactorial, says Mina Massaro-Giordano, MD, making identifying and treating dry eye important for quality of life.

Zongertinib shows promising results in HER2-mutant NSCLC, offering high response rates and improved quality of life with minimal toxicity.

Rebecca Haberman, MD, of NYU Langone Health, highlights precision medicine and potential prevention strategies, two areas of promising psoriatic arthritis research.

Although her recent study acknowledges potential differences between White and non-White patients with psoriatic arthritis (PsA), Rebecca Haberman, MD, NYU Langone Health, emphasizes the need for further research to understand what these differences are and why they occur.

Recognizing psoriasis and psoriatic arthritis (PsA) in non-White patients is the first step toward providing more equitable care for those of all backgrounds with PsA, according to Rebecca Haberman, MD, of NYU Langone Health.